Literature DB >> 25352398

Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.

Takumi Kumai1,2, Kensuke Oikawa1, Naoko Aoki1, Shoji Kimura1, Yasuaki Harabuchi2, Hiroya Kobayashi1.   

Abstract

BACKGROUND: Epidermal growth factor receptor (EGFR)-targeted therapy has been widely accepted as a promising treatment for solid tumors. Steroid treatment is used to prevent adverse effect of anti-EGFR antibody; however, influence of steroids in the antitumor activity of targeted antibody remains poorly understood. Herein, we demonstrated the impact of steroids in induced antibody-dependent cellular cytotoxicity (ADCC) activity of natural killer (NK) cells by cetuximab.
METHODS: Various numbers of NK cells from healthy donors were co-cultured with tumor and/or cetuximab with or without dexamethasone. After incubation, NK cells, ADCC activity, survival, and activation markers expression were determined.
RESULTS: Clinical concentration of dexamethasone treatment clearly inhibited cetuximab-induced ADCC activity of NK cells against head and neck squamous cell carcinoma (HNSCC) and colon cancer. Dexamethasone decreased the activation marker CD69 expression on NK cells.
CONCLUSION: This is the first report that shows the negative affect of steroids in cancer treatment using therapeutic antibody. Attention needs to be paid for using steroids in tumor treatment.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  antibody-dependent cellular cytotoxicity (ADCC); cetuximab; head and neck squamous cell carcinoma (HNSCC); natural killer (NK) cells; steroid

Mesh:

Substances:

Year:  2015        PMID: 25352398     DOI: 10.1002/hed.23906

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  A peptide inhibitor of antibody-dependent cell-mediated cytotoxicity against EGFR/folate receptor-α double positive cells.

Authors:  Koichi Sasaki; Yoshiki Miyashita; Daisuke Asai; Daiki Funamoto; Kazuki Sato; Yoko Yamaguchi; Yuji Mishima; Tadafumi Iino; Shigeo Takaishi; Jun Nagano; Akihiro Kishimura; Takeshi Mori; Yoshiki Katayama
Journal:  Medchemcomm       Date:  2018-02-26       Impact factor: 3.597

2.  Small-Molecule Immunosuppressive Drugs and Therapeutic Immunoglobulins Differentially Inhibit NK Cell Effector Functions in vitro.

Authors:  Amandine Pradier; Maria Papaserafeim; Ning Li; Anke Rietveld; Charlotte Kaestel; Lyssia Gruaz; Cédric Vonarburg; Rolf Spirig; Gisella L Puga Yung; Jörg D Seebach
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

3.  A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.

Authors:  Sumithira Vasu; Jessica K Altman; Geoffrey L Uy; Martin S Tallman; Ivana Gojo; Gerard Lozanski; Ute Burkard; Annika Osswald; Pamela James; Björn Rüter; William Blum
Journal:  Haematologica       Date:  2022-03-01       Impact factor: 11.047

4.  WX-0593 combined with an epithelial growth factor receptor (EGFR) monoclonal antibody in the treatment of xenograft tumors carrying triple EGFR mutations.

Authors:  Qingmei Zheng; Dongmei Chen; Xinmei Wang; Yingying Yang; Shuyong Zhao; Xin Dong; Cuicui Ma; Xin Zhang; Huicheng Duan; Yan Sun; Shansong Zheng
Journal:  Ann Transl Med       Date:  2022-06

5.  Regulatory effects of dexamethasone on NK and T cell immunity.

Authors:  Liying Chen; Mikael Jondal; Konstantin Yakimchuk
Journal:  Inflammopharmacology       Date:  2017-11-20       Impact factor: 4.473

6.  Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours.

Authors:  Walter Fiedler; Herbert Stoeger; Antonella Perotti; Guenther Gastl; Jens Weidmann; Bruno Dietrich; Hans Baumeister; Antje Danielczyk; Steffen Goletz; Marc Salzberg; Sara De Dosso
Journal:  ESMO Open       Date:  2018-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.